- Barrett’s esophagus and esophageal adenocarcinoma: from molecular pathogenesis to novel therapeutic targets
- Award date
- 26 September 2017
- Number of pages
- Document type
- PhD thesis
- Faculty of Medicine (AMC-UvA)
Despite latest improvements in diagnostics and therapeutics, esophageal cancer is still the sixth most frequent cause of death related to cancer worldwide. Patients that suffer from this cancer have very poor prognosis, with 5-year survival rates of 15-20%. This is mostly due to late clinical presentation with advance disease. Strikingly, especially in western countries, the incidence of the histologic subtype esophageal adenocarcinoma (EAC) increased dramatically over the past twenty years. Unfortunately, standard treatments, such as chemoradiotherapy and/or surgery, seem to be not effective. In the first part of this thesis, I’ve approached the study of molecular key events involved in the development of Barrett’s esophagus, one of the major risk factor associated with the development of EAC. Specifically, I’ve tried to understand the signalling pathways activated by the chronic gastro-esophageal reflux exposure, in order to unveil novel therapeutic targets at which preventive therapies can be directed. In the second part of this thesis I’ve focused on the immunobiology of EAC. I’ve tested novel methodologies for boosting the host’s anti-tumor immune response and, I’ve attempted to understand molecular mechanisms that can lead to tumor immune evasion. Only a deep understanding of the described molecular pathways can lead the way to the development of more effective therapeutic approaches, such as, immunotherapy.
- Please note that the acknowledgements section is not included in the thesis downloads.
Thesis (Embargo until 26 September 2019)
Chapter 3: Glyco-conjugated bile acids drive the development of columnar metaplasia at the squamo-columnar junction in mice (Embargo until 26 September 2019)
Chapter 5: Expression of the MHC class I pathway correlates with an immune-active tumor microenvironment and treatment outcome in esophageal adenocarcinoma (Embargo until 26 September 2019)
Chapter 6: Summary and general discussion (Embargo until 26 September 2019)
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.